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Introduction
Gastric cancer (GC) is a leading cause of global cancer mortality 
(1), with a particularly high prevalence in East Asia. With the excep-
tion of Japan and South Korea, where the absolute GC incidence 
is sufficiently high to enable cost-effective endoscopic screening, 
today most patients with GC are diagnosed at advanced stages of 
the disease, resulting in low overall survival (2). Targeted agents 
approved for clinical use in GC include trastuzumab for human epi-
dermal growth factor receptor 2–positive (HER2-positive) GC (3), 
ramicurumab (VEGFR2) (4), and immuno-oncology agents such as 
pembrolizumab (5) and nivolumab (6). However, these treatments 
are typically only effective in small subsets of patients with GC, 
and clinical trials evaluating alternative GC molecular targets have 
proved disappointing (7–10). Investigating the basic mechanisms 
of GC tumorigenesis may therefore elucidate the early steps in gas-
tric malignancy and lead to new therapeutic interventions.
Reactivation of telomerase is a pivotal step in cancer initia-
tion. Telomere sequences at chromosome ends are lost during 
successive rounds of DNA replication, and critically short telo-
meres can induce cellular senescence and apoptosis. Telomer-
ase is an RNA-dependent DNA polymerase consisting of an 
RNA component (TERC) and a protein catalytic subunit (TERT) 
that can lengthen a chromosome’s telomeres. TERT is normally 
expressed in human stem and germ cells but is silenced in differ-
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TERT repressor and validated its function through in vitro and 
in vivo studies. We provide evidence that in GC, EBF1 function 
is suppressed by various mechanisms, including epigenetic inac-
tivation, dominant-negative mutations, and large-scale genomic 
alterations affecting EBF1 cis-binding regions at the TERT pro-
moter. EBF1 inhibition may therefore contribute to TERT reex-
pression and activity in GC.
Results
EBF1 TF expression is negatively associated with TERT. To investi-
gate TERT expression in GC, we queried RNA-Seq profiles of pri-
mary GCs from The Cancer Genome Atlas (TCGA) consortium (n 
= 415 GCs, n = 35 normal samples), in-house databases of primary 
tumors (n = 18 tumor/normal [T/N] pairs of GCs), and GC cell 
lines (n = 63). We found that TERT was significantly upregulated 
in GC samples compared with normal samples (P = 1.9, Figure 1A 
× 10–10; Supplemental Figure 1A; supplemental material available 
online with this article; https://doi.org/10.1172/JCI126726DS1) 
and exhibited variable expression across GC lines (Supplemental 
Figure 1B). TERT overexpression was greater in GCs with chro-
mosomal instability (CIN) or microsatellite instability (MSI) com-
pared with genome-stable (GS) or EBV-positive tumors (Figure 
1A). These results are consistent with previous independent stud-
ies reporting increased TERT expression in GC (see Discussion 
and refs. 22–24). To determine the prevalence of TERT promoter 
point mutations in GC, we surveyed whole-genome sequences 
(WGSs) of 212 GCs and matched normal samples (25) but detected 
no mutations at previously reported TERT mutational hotspots 
(C228T and C250T), consistent with previous reports that TERT 
promoter hotspot mutations are rare in GC (18).
We sought to identify trans-acting TFs that regulate TERT 
in GC. Hypothesizing that TERT-regulatory TFs should exhibit 
genomic occupancy of the TERT promoter region and also sys-
tematic relationships with TERT expression, we proceeded to cor-
relate TERT expression levels (inferred from TCGA GCs) against 
the expression patterns of 26 TFs predicted to bind around the 
TERT transcription start site (TSS) (± 10 kb). These 26 factors 
were identified on the basis of their predicted ability to bind to the 
TERT promoter region using ChIP-Seq data from the ENCODE 
ChIP-Seq database (https://genome.ucsc.edu/ENCODE/3). 
Confirming the utility of this approach, this analysis reidentified 
several previously known TERT regulators, such as MYC (TERT 
activator) and MXI1 (TERT repressor) (26, 27). Notably, we 
observed that TERT expression levels were negatively correlated 
with the EBF1 TF, ranking second in significance among the puta-
tive TERT-regulatory TFs (R = –0.20, P = 1.2 × 10–5; Figure 1B). 
We extended our analysis to 2 other GC expression microarray 
cohorts and again observed similar significant negative correla-
tions between TERT and EBF1, thus validating this observation in 
independent cohorts (Figure 1C).
Historically studied as a TF in B-lineage immune cells, EBF1 
expression has been recently described in solid tumors such as 
breast cancer, cholangiocarcinoma, and glioblastoma (28, 29). 
To explore EBF1 expression in stomach tissues, we mined the 
Genotype–Tissue Expression (GTEx) database (https://www. 
gtexportal.org/home/) and observed that EBF1 is expressed in 
many human tissues and cell types including stomach (Supple-
entiated somatic cells and transcriptionally reactivated in up to 
90% of human malignancies (11, 12). TERT reactivation is a driver 
of oncogenic alteration, contributing to cellular transformation, 
immortalization, and oncogenic development in many cancer 
types. Clinically, high TERT expression levels have been associ-
ated with aggressive disease. In GC specifically, high TERT lev-
els have been associated with poor prognosis, advanced disease 
stage, and lymphatic metastasis and invasion (13–15).
Despite their importance, the cellular mechanisms driving 
the transcriptional reactivation of TERT in cancers remain poorly 
described, particularly in the case of GC. In certain cancers, TERT 
promoter somatic mutations (C250T and C228T) have been 
described as a major mechanism of telomerase reactivation (16, 
17), however, these promoter hotspot mutations appear to be infre-
quent in GC (<1%) (18). Besides promoter point mutations, large-
scale genomic alterations such as enhancer hijacking (19) and copy 
number alterations (20) affecting TERT have been reported, and 
at the trans-regulatory level, oncogenic transcriptional activators 
(Sp1, c-MYC, AP2, and HIF-1) and tumor-suppressive transcrip-
tional repressors (p53, Menin, and WT1) may also regulate TERT 
(21). To date, however, specific mechanisms underlying TERT 
reactivation in GC remain largely unknown.
In this study, we focused on investigating molecular processes 
that govern TERT expression in GC. By integrating genomic 
data from primary GCs and GC cell lines, we identified the early 
B cell factor 1 (EBF1) transcription factor (TF) as a candidate 
Figure 1. EBF1 TF expression is negatively associated with TERT. (A) 
Expression of TERT in normal gastric (n = 35) and GC samples (n = 415) 
from TCGA consortium. Q values were determined by Wilcoxon’s rank-sum 
test with FDR multiple testing correction. RSEM, RNA-Seq by expecta-
tion-maximization (https://github.com/deweylab/RSEM). (B) Correlation 
of mRNA levels between TERT and TFs (ENCODE ChIP-Seq database) at 
genomic regions flanking the TERT TSS. Correlation coefficients were 
computed using the normalized expression matrix from TCGA. *Q < 0.05, 
**Q < 0.01, and ***Q < 0.001, by Pearson’s correlation test with FDR 
multiple testing correction. (C) A significant negative correlation was found 
between TERT and EBF1 mRNA levels in the South Korean and Singapore 
cohorts. Top: microarray data for 96 GC samples from the Korean cohort 
(median-centered, log-transformed). Bottom: microarray data for 185 GC 
samples from the Singapore (SG) cohort (log2 expression level). P values 
were determined by Pearson’s correlation test. (D) Graph shows EBF1 and 
TERT expression levels based on RNA-Seq data for 63 GC lines. FPKM, frag-
ments per kilobase per million mapped reads. (E) TaqMan qPCR validation 
of EBF1 expression levels using in-house normal stomach tissues. (F) EBF1 
expression levels in normal gastric organoids (microarray). RMA, robust 
multiarray average. (G) Western blot analysis of EBF1 protein expression in 
GC lines. Ctrl, control. (H) Expression of EBF1 in normal gastric (n = 35) and 
GC samples (n = 415) from TCGA. P value was determined by Wilcoxon’s 
rank sum test. (I) EBF1 immunohistochemistry for GC tissues and normal 
gastric epithelium. Left: normal gastric epithelium with EBF1 expression 
(brown); middle: GC cells with EBF1 expression in 15% of the tumor cells 
(brown); right: intestinal-type GC cells with complete loss of EBF1 expres-
sion, endothelial cells and lymphocytes in the tumor stroma were EBF1+ 
(brown). Original magnification, x40. Red arrows indicate stained cells. (J) 
Distribution of immunohistochemical scores for EBF1 protein expression in 
51 GCs and matched normal tissues, connected by black lines. P value was 
determined by 2-sided t test. (A and H) For the box-and-whisker plots, the 
lines within boxes indicate the median, the bounds of the boxes indicate 
the upper and lower quartiles, the whiskers indicate the minimum and 
maximum values, and the separated points indicate outliers.
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with different clinicopathological characteristics, EBF1 loss was 
more frequent in diffuse-type GCs and poorly differentiated GCs 
(P = 0.001 and P = 0.002 respectively, n = 109 patients; Supple-
mental Table 1). We also observed a trend toward more frequent 
EBF1 loss in patients with a higher number of lymph node metas-
tases (P = 0.052, n = 109 patients; Supplemental Table 1).
EBF1 is transcriptionally silenced in GC via repressive histone 
modifications and DNA methylation. To explore potential mech-
anisms underlying EBF1 downregulation in GC, we found a pro-
moter occupancy/expression correlation similar to that depicted 
in Figure 1B, but this time analyzing the EBF1 instead of the 
TERT  promoter region. Correlation of TFs predicted to bind the 
EBF1 promoter region (± 2.5 kb) to EBF1 mRNA expression levels 
revealed a strong negative correlation of EBF1 with 2 poly-
comb-repressive complex 2 (PRC2) subunits: EZH2 (R = –0.44, P 
< 0.00001) and SUZ12 (R = –0.29, P = 2.4 × 10–10) (Figure 2A). We 
queried EZH2 and SUZ12 ChIP-Seq data from the ENCODE data-
base and found EZH2 and SUZ12 occupancy at the EBF1 promoter 
in various cell types (Figure 2B). As PRC2 is known to catalyze the 
H3K27me3-repressive histone mark, we performed H3K27me3 
ChIP-Seq analysis and confirmed H3K27me3 enrichment at the 
EBF1 TSS locus in EBF1-low (AGS, IM95, and SNU484) but not 
EBF1-high GC cells (YCC11) (Figure 2B). Given that histone mod-
ifications and DNA methylation often cooperate to regulate gene 
expression (34), we also evaluated DNA methylation levels at the 
EBF1 promoter using Illumina 450K DNA Methylation Arrays. 
We found that EBF1-low cell lines had high to moderate levels of 
EBF1 promoter DNA methylation (high, AGS and IM95; moderate, 
SNU484), whereas the EBF1-high cell line YCC11 showed no EBF1 
promoter DNA methylation.
We explored whether targeting EZH2, the catalytic subunit of 
PRC2, might reactivate EBF1. Knockdown of EZH2 by siRNA in 
the GC lines AGS and SNU484 caused a 3.2- to 7.5-fold increase 
in EBF1 mRNA levels (Supplemental Figure 2, A and B). We then 
tested the effects of EZH2 pharmacologic inhibition using 2 dis-
tinct EZH2-inhibitory compounds, GSK126 and GSK343 (Figure 
2C and Supplemental Figure 2C). In SNU484 cells, EZH2 inhibi-
tion was accompanied by a 40- to 87-fold increase in EBF1 expres-
sion levels. However, in AGS cells, EZH2 monoinhibition did not 
induce similarly strong changes in EBF1 expression. To further 
explore this observation, we noted recent studies have shown that 
multiple epigenetic pathways often act in a coordinated and com-
binatorial manner to repress target promoters. For example, EZH2 
requires histone deacetylases (HDACs) to silence targets (35), and 
EZH2 can directly control DNA methylation by recruiting DNA 
methyltransferase (DNMT) (34). We thus explored whether EBF1 
might also be regulated by DNMTs and HDACs. Examination of 
methylation array data from 191 GCs from the TCGA consortium 
revealed higher levels of EBF1 promoter DNA methylation in GCs 
with low EBF1 expression (i.e., higher β values), whereas GCs with 
high EBF1 expression exhibited lower DNA methylation levels 
(i.e., lower β values; Figure 2D). We observed a similar trend in a 
pairwise fashion in an in-house cohort of GCs with matched nor-
mal samples (n = 18 T/N pairs; Figure 2E and Supplemental Figure 
2D; the same 12 CpG probes were measured in both cohorts). The 
degree of the β value methylation differences is fully consistent 
with definitions of hypermethylation by other independent stud-
mental Figure 1C and ref. 30). To confirm that EBF1 is expressed in 
GC epithelial cells, we compared EBF1 and TERT RNA-Seq expres-
sion levels across a panel of 63 GC cell lines. GC cell lines with 
high EBF1 expression exhibited no or low TERT transcript levels, 
whereas the majority of cell lines lacking EBF1 expression dis-
played high TERT expression (Figure 1D). EBF1 mRNA expression 
in stomach was further confirmed by TaqMan quantitative PCR 
(qPCR) analysis of a diverse collection of gastric-related samples, 
including primary normal gastric tissues (n = 6), GC cell lines (n = 
4); gene expression analysis of TCGA normal gastric tissues (RNA-
Seq, n = 39); data from 2 additional public data sets (31, 32); and 
analysis of normal gastric organoids (n = 6) (Figure 1, E and F, Sup-
plemental Figure 1, D–G, and ref. 33) . To confirm EBF1 expression 
at the protein level, we performed Western blotting using anti-
EBF1 antibodies validated by both predicted protein size (Figure 
1G, left and middle) and siRNA-knockdown assays (Figure 1G, 
right). We confirmed endogenous EBF1 protein expression in cell 
lines showing high EBF1 transcript levels and low EBF1 protein 
expression in cell lines expressing low levels of EBF1 transcripts.
Compared with normal gastric tissues, EBF1 transcripts were 
significantly downregulated in GC (TCGA samples, P = 0.012; Fig-
ure 1H) — a pattern opposite that of TERT transcript levels. To con-
firm EBF1 protein expression in primary GCs, we performed EBF1 
immunohistochemical analysis on a panel of GCs and matched 
normal tissues. This analysis revealed EBF1 expression in scat-
tered nuclei of normal gastric epithelium and GC cells (Figure 1I), 
ranging from 0% to 25% of cells (Figure 1J). Similar to the gene 
expression data, primary GCs exhibited significantly lower EBF1 
immunohistochemical scores than did normal gastric tissues (P = 
0.0008, n = 51 T/N pairs; Figure 1J). When compared with GCs 
Figure 2. EBF1 is transcriptionally silenced in GC via repressive histone 
modifications and DNA methylation. (A) Correlation of mRNA expression 
levels between EBF1 and TFs at genomic regions flanking the EBF1 TSS. 
Correlation coefficients were computed using the normalized expression 
matrix from TCGA (n = 415 tumors, n =  35 normal samples). *Q < 0.05, **Q 
< 0.01, and ***Q < 0.001, by Pearson’s correlation test with FDR multiple 
testing correction. (B) H3K27me3, EZH2, and SUZ12 signals flanking the 
EBF1 TSS. Top: RNA-Seq tracks depict EBF1 expression in GC lines. Bottom 
left: H3K27me3, EZH2, and SUZ12 enrichment. Yellow bar indicates the 
EBF1 promoter (TSS ± 2.5 kb). Bottom right: DNA methylation levels of 
GC lines. Colored graph shows the average β value of 12 CpG probes in the 
5′-UTR and TSS of EBF1. EZH2 and SUZ12 ChIP-Seq data are from the 
ENCODE database. Layered signals from multiple cell lines are shown for 
EZH2 (H1 human embryonic stem cells [H1-hESCs], human mammary 
epithelial cells [HMECs], human umbilical vein endothelial cells [HUVECs], 
normal human astrocytes [NHAs], normal human epidermal keratinocytes 
[NHEKs], and normal human lung fibroblasts [NHLFs]). The SUZ12 profile 
is from H1-hESCs. (C) EZH2 and EBF1 expression levels in SNU484 cells 
after drug treatment. (D) DNA methylation 450K array data from TCGA. 
Data were plotted for the top and bottom 25th percentiles of EBF1-ex-
pressing samples (n = 191). (E) In-house DNA methylation 450K array data 
for 18 T/N GC pairs. Heatmap shows GCs with or without loss of EBF1. (D 
and E) Data are from 12 CpG probes in the 5′-UTR and TSS region of EBF1. 
(F) Response patterns of EBF1 and TERT mRNA levels following drug 
treatments. (C and F) Control cells were treated with DMSO. *Q < 0.05, by 
2-sided t test with FDR multiple testing correction. qPCR results are shown 
as the mean ± SD of technical triplicates. All data are representative of 3 
independent experiments. (G) H3K27me3 enrichment at the EBF1 locus 
from GC cell lines with DMSO, 5-aza, and GSK126 treatment. Red arrows 
indicate a decrease in H3K27me3 enrichment.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
6 jci.org
Figure 3. EBF1 TF negatively regulates TERT and oncogenic development in vitro and in 
vivo. (A) Individual si-EBF1 silencing caused TERT overexpression in YCC11. Two individual 
EBF1 siRNAs were used (left) and resulted in TERT upregulation (right) in YCC11. (B) TRAP 
assay showed an increase in telomerase activity caused by overexpression of TERT via EBF1 
knockdown. (C) Western blotting showed increased EBF1 protein levels after overexpres-
sion in GC lines. (D and E) EBF1 overexpression caused TERT reductions and a decrease in 
telomerase activity. (F and G) Cell proliferation capacity after EBF1 overexpression in GC 
cell lines. Proliferation assays and monolayer colony formation assays showed a dramatic 
decrease in cell proliferation capacity after EBF1 overexpression. (H and I) In vivo effects of 
EBF1 overexpression on tumorigenesis. (H) NOD/SCID mouse tumor volumes after injection 
of either endogenous EBF1 (vector, blue) or EBF1-overexpressing (EBF1-OE) AGS GC cells. 
Tumor volumes were measured every 3 days. n = 6 mice per group. (I) Image of harvested 
tumors after an experimental period of 10 weeks. Tumor sizes are shown in centimeters. #Q 
< 0.05, by 2-sided t test with FDR multiple testing correction (A, B, and D). *P < 0.05, **P 
< 0.01, and ***P < 0.001, by 2-sided t test (E, F, and H). Error bars indicate the SD. RT-PCR 
results are shown as the mean ± SD of technical triplicates. All data are representative of 3 
independent experiments.
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ies (36, 37). For orthogonal validation of the β value DNA methyl-
ation levels, we performed quantitative DNA methylation assays 
(MethylLight) in 8 T/N pairs to determine EBF1 promoter DNA 
methylation levels (4 pairs with the highest methylation levels in 
GCs and 4 pairs randomly selected from GCs with low methyla-
tion levels; Supplemental Figure 2E). The quantitative DNA meth-
ylation results were concordant with patterns from the 450K DNA 
methylation β values. Taken collectively, these results suggest that 
approximately half (40%–55%) of primary GCs with loss of EBF1 
expression have high levels of EBF1 promoter methylation.
To determine whether epigenetic drug combinations might 
affect EBF1 expression, we performed single-, double-, and triple- 
agent combination treatments of AGS and SNU484 cells with 
EZH2 inhibitors (GSK126), DNMT inhibitors (5-aza-2′-deoxycyti-
dine [5-aza]), and the HDAC inhibitor trichostatin A (TSA). Treat-
ment of AGS and SNU484 cells with 5-aza caused reexpression 
of EBF1 that was approximately 4-fold and 22-fold over levels in 
control cells, respectively (Figure 2F and Supplemental Figure 2F), 
suggesting that the magnitude of EBF1 reexpression induced by 
5-aza is cell line specific, which is supported by an independent 
study of GC cell lines (38). For HDAC inhibition, similar EBF1 
increases were achieved by treatment with either TSA or vorinos-
tat, a more specific HDAC inhibitor (Supplemental Figure 2G and 
ref. 39). Notably, compared with single-agent treatments, combi-
natorial epigenetic therapies consistently induced substantially 
higher levels of EBF1 expression, demonstrating that EBF1 is inac-
tivated in GC through diverse epigenetic pathways (PRC2, DNA 
methylation, and HDAC). Supporting this hypothesis, in AGS cells 
a triple combination of epigenetic therapies (5-aza plus TSA plus 
GSK126) induced the most dramatic EBF1 upregulation relative to 
single- and dual-agent treatments (Figure 2F).
We also asked whether epigenetic treatment affected EBF1- 
associated histone modifications and/or DNA methylation. Using 
H3K27me3 ChIP-Seq, we confirmed decreased H3K27me3 sig-
nals at the EBF1 locus after treatment with either GSK126 or 5-aza 
in 2 cell lines (Figure 2G). Quantitative DNA methylation analysis 
of both cell lines before and after 5-aza treatment also confirmed 
significant decreases in DNA methylation levels after treatment 
with 5-aza but not GSK126 (Supplemental Figure 2H). However, 
we did not observe convincing alterations in H3K27ac signals after 
epigenetic treatment (Supplemental Figure 2I). It is possible that 
our experimental conditions and selection time points may have 
been too short to observe changes in H3K27ac or, alternatively, 
that inhibition of EZH2 (by GSK126) or DMNT (by 5-aza) may 
not be sufficient to alter H3K27ac patterns. Taken collectively, 
these results suggest that EBF1 is transcriptionally silenced in GC 
through a combination of repressive histone modifications and 
DNA methylation.
Besides the EBF1 promoter, we also investigated distal cis- 
regulatory element regions upstream and downstream of EBF1 
(TSS +100 kb/–1000 kb). We identified 43 potential enhancers 
associated with the EBF1 locus. Of these 43, we found that 5 pre-
dicted enhancers (Supplemental Figure 2J, blue highlights) had 
differential H3K27ac signals between EBF1-high cell lines (LMSU 
and Hs746T) and EBF1-low cell lines (AGS and SNU484) (P < 0.05, 
1-sided Student’s t test). Supporting their designation as enhancer 
elements, these 5 enhancers were also associated with increased 
H3K4me1 and ATAC-Seq (assay for transposase-accessible chro-
matin using sequencing) signals in EBF1-high cell lines, but not 
in EBF1-low cell lines, and 3 of these enhancers exhibited sig-
nificant interactions with the EBF1 promoter in public databases 
of Promoter Capture Hi-C (pcHi-C) data (Supplemental Figure 2J; 
arc lines; P  < 0.01; promoter/capture point: green bar; ref. 40).
The EBF1 TF negatively regulates TERT and oncogenic develop-
ment in vitro and in vivo. Consistent with EBF1 being a TERT repres-
sor, enhancement of EBF1 reexpression by combinatorial epigen-
etic therapies also caused TERT silencing in both cell lines (Figure 
2F and Supplemental Figure 2F). To specifically test whether EBF1 
regulates TERT, siRNA-mediated depletion of endogenous EBF1 
using either pooled or independent EBF1 siRNAs in YCC11 cells, 
which express high EBF1 levels, resulted in 2.3- to 3-fold increases 
in TERT RNA levels, as determined by TaqMan qPCR assays (Fig-
ure 3A and Supplemental Figure 3A). Notably, this degree of TERT 
induction is comparable to expression levels associated with TERT 
promoter hotspot mutations (41). Using telomeric repeat ampli-
fication protocol (TRAP) assays, we also confirmed that EBF1 
knockdown caused 1.8- to 7.9-fold increases in telomerase activ-
ity (Figure 3B). These results were replicated and confirmed in 2 
additional GC cell lines (Hs746T and HGC27), each using 2 inde-
pendent EBF1 shRNAs (Supplemental Figure 3B). In the reciprocal 
experiment, we induced overexpression of EBF1 in AGS, SNU484, 
and IM95 cells, which express low or no EBF1. Western blotting 
confirmed increased levels of EBF1 protein in the EBF1-transduced 
cell lines (Figure 3C), and EBF1 overexpression resulted in a 26% 
to 46% decrease in TERT mRNA levels (Figure 3D). Similar-
ly, using TRAP assays, we confirmed that EBF1 overexpression 
caused a 30% to 40% decrease in telomerase activity (Figure 3E 
and Supplemental Figure 3C). These findings suggest that EBF1 is 
a negative regulator of TERT in GC.
To assess whether EBF1 plays a functional role in GC, we per-
formed proliferation and monolayer colony formation assays and 
found that overexpression of EBF1 in multiple cell lines dramati-
cally reduced cellular proliferation and monolayer colony forma-
tion (Figure 3, F and G). In vivo, we tested NOD/SCID xenograft 
mice injected with AGS cells with or without EBF1 overexpression. 
After 41 days, the tumors formed from EBF1-overexpressing GC 
cells were significantly smaller than those formed from control 
cells (Figure 3, H and I). The tumor growth–inhibiting effect of 
EBF1 was sustained throughout the entire experimental period of 
approximately 10 weeks. To identify biological pathways affected 
by EBF1 overexpression, we sequenced the transcriptomes of 
EBF1-overexpressing cells. Using the Genomic Regions Enrich-
ment of Annotations Tool (GREAT) algorithm (42), we found 
that genes downregulated by EBF1 overexpression were enriched 
in pathways related to chromosomal organization, reassuringly 
including TERT (Supplemental Figure 3D, left). Reciprocally, we 
found that genes upregulated by EBF1 overexpression, including 
FAS, HIF1A, and AIFM2, were enriched in pathways such as cell 
death regulation (Supplemental Figure 3D, right).
EBF1 exhibits dominant-negative mutations in GC. To obtain 
further evidence of EBF1 disruptions in GC, we investigated 
whether EBF1 exhibits somatic DNA mutations that might alter 
EBF1 function. We queried exome- and whole-genome sequenc-
ing data for 459 GCs from public and in-house data sets and iden-
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in the DBD GH loop (aa 193–210), which would be predicted to 
cause greater loop flexibility and a longer time to attain a proper 
DNA-binding conformation (Figure 4G). Also, compared with the 
WT EBF1 DBD, we found that the Q196P and R209Q mutants 
had energetically less favorable associations with DNA (Supple-
mental Table 2). These results suggest that Q196P and R209Q 
EBF1 DBDs are likely to bind less stably to DNA compared with 
WT EBF1. To confirm this prediction, we performed EMSAs using 
recombinant EBF1 proteins. Compared with WT EBF1, Q196P- or 
R209Q-mutated EBF1 did not display DNA binding to probes con-
taining EBF1-binding motifs (Figure 4H).
The EBF1 mutations observed in GC were heterozygous, 
indicating that EBF1-mutated GCs may still express a WT copy 
of EBF1. However, EBF1 has been shown to function as a dimer 
(43), raising the possibility that the Q196P and R209Q mutations 
may function as dominant-negative isoforms. To test this pos-
sibility, we induced co-overexpression of WT and Q196P EBF1 
in AGS cells. We found that cells coexpressing WT and Q196P 
EBF1 had compromised proliferation rates, decreased monolayer 
colony formation, and reduced TERT mRNA levels, intermediate 
between EBF1 WT and Q196P-mutant cells (Figure 4, I–L, and 
Supplemental Figure 4G). These results suggest that certain EBF1 
DBD mutations have dominant-negative activity.
EBF1 binds to a TERT 5′ proximal cis-regulatory element. To 
determine whether EBF1 occupies cis-regulatory elements at the 
TERT promoter, we performed EBF1 ChIP-Seq in EBF1-expressing 
GC cell lines (HGC27, Hs746T, YCC11, and AGS with endogenous 
EBF1). We also analyzed AGS cells overexpressing either WT EBF1 
or the EBF1 DNA–binding mutants. Motif analysis of the EBF1 
ChIP-Seq peaks revealed that the top-ranked de novo consensus 
binding motif matched previously known EBF1 factors (Figure 5A 
and refs. 44, 45). We identified 2 EBF1-binding peaks in the TERT 
5′ proximal region, at –2.3 kb and –4 kb, both with EBF1-binding 
motifs (hereafter referred to as peak 1 and peak 2, respectively) 
(Figure 5B). We observed no EBF1 binding at peaks 1 or 2 in cell 
lines lacking endogenous EBF1 or in cells over expressing mutant 
EBF1 (Q196P or R209Q), further demonstrating that certain EBF1 
DBD mutations have decreased DNA-binding capacity (Figure 5B). 
Besides peak 1 and peak 2 at the TERT 5′ proximal region, expanded 
analysis of the TERT genomic locus did not reveal significant or 
consistent EBF1 binding at other distal regions, suggesting that 
peaks 1 and 2 are the predominant EBF1-binding regions at TERT 
in GC (Supplemental Figure 5A).
To determine whether the TERT 5′ proximal region contain-
ing peaks 1 and 2 has properties of an enhancer element, we then 
mapped potential cis-regulatory elements and chromatin features 
associated with the TERT 5′ proximal region using Nano-ChIP-
Seq histone profiles (46). Specifically, we compared GC cell lines 
expressing high and low TERT transcription levels and also primary 
GCs relative to matched normal tissues (Figure 5C and sequenc-
ing statistics in Supplemental Table 3). Concentrating on H3K27ac 
and H3K4me1 modifications corresponding to activity and 
enhancer marks, respectively (47), we reidentified a previously 
described TERT-regulatory element 21 kb upstream of the TERT 
TSS, supporting the reliability of our data (Figure 5C, gray bar, and 
ref. 48). Notably, we observed increased H3K27ac and H3K4me1 
signals at peak 2 in primary GCs compared with matched normal 
tified 14 GCs with EBF1 coding missense mutations (Figure 4A). 
Of these, 50% of the mutations were localized to the EBF1 DNA–
binding domain (DBD), targeting highly conserved sequence res-
idues (Supplemental Figure 4A). To distinguish passenger from 
driver mutations, we individually cloned the EBF1 DBD mutations 
and expressed the EBF1 mutants in 2 GC cell lines that normally 
do not express EBF1 (AGS and SNU484). In both cell lines, West-
ern blotting confirmed comparable expression levels of both WT 
and mutant EBF1 proteins (Figure 4B and Supplemental Figure 
4B). Proliferation and monolayer colony formation assays showed 
that WT EBF1 dramatically reduced cellular proliferation and 
monolayer colony formation (Figure 4, C and D, and Supplemen-
tal Figure 4, C and D). In contrast, the EBF1 mutants Q196P and 
R209Q had a proliferative capacity similar to that of empty vector 
controls, demonstrating that Q196P and R209Q mutations are 
sufficient to abolish EBF1 activity. I139T, R111W, and R242W/Q 
mutants exhibited a proliferative capacity similar to that of WT 
EBF1 and were designated passengers.
To investigate the structural impact of Q196P and R209Q 
mutations on EBF1 activity, we performed 3D structural analysis 
and molecular dynamic (MD) simulations. Mapping of the Q196P 
and R209Q mutations to EBF1-DNA complex structures revealed 
that these residues are probably not directly involved in DNA con-
tact or DNA recognition (Figure 4, E and F). Using MD simulations 
to investigate the effect of these mutations at the atomic level, we 
determined that both WT and mutant EBF1 DBDs are predicted 
to exhibit similar integrity and stability under both unbound 
and DNA-bound states (Supplemental Figure 4, E and F). How-
ever, during the unbound EBF1 simulations, the Q196P and 
R209Q mutants showed loss of intramolecular hydrogen bonds 
Figure 4. EBF1 exhibits dominant-negative somatic mutations in GC. (A) 
Distribution of EBF1 coding mutations in 14 GC patients with annotated 
functional domains. Each dot represents 1 patient. (B) Western blotting 
revealed equal levels of EBF1 protein abundance after overexpression of 
WT and mutant EBF1 in AGS cells. (C and D) Proliferation assays (C) and 
monolayer colony formation assays (D) showed cell proliferation capacity 
after overexpression of WT and mutant EBF1 in GC cells. Error bars indicate 
SD. (E) 3D structural analysis of EBF1 and missense mutations. The x-ray 
crystal structure reveals that 2 EBF1 protomers (green and cyan ribbons) 
are predicted to dimerize and bind to DNA (orange ribbon with blue 
ladders). Purple sticks and labels indicate the positions of GC-associated 
missense mutations on 3 functional domains. HLH, helix-loop-helix. (F 
and G) Alterations of DNA-binding loop flexibility by EBF1 mutations. (F) 
EBF1 DBDs are represented by green ribbons. Purple sticks indicate the 
position of 4 missense mutations. The 3 orange beads mark Cα atoms 
of R63, N172, and P205. Double helix shows the relative orientation of 
DNA in the complex. (G) Distance distributions of specified Cα atoms 
obtained from MD simulations of unbound EBF1 DBD. Vertical dashed lines 
indicate the distances measured from x-ray crystal structures. (H) EMSAs 
showed that Q196P or R209Q mutated recombinant EBF1 protein did not 
have DNA binding to probes containing EBF1-binding motifs. (I) Western 
blots showed similar protein levels of WT EBF1, Q196P-mutant EBF1, and 
combined WT plus Q196P-mutant EBF1 after overexpression. Proliferation 
assay (J) and monolayer colony formation assay (K) showed cell prolif-
eration capacity after overexpression. Error bars indicate SD. (L) Gene 
expression levels (RNA-Seq) of AGS cells after retroviral infection with 
either empty vector (black), WT EBF1 (blue), Q196P-mutant EBF1 (red), or 
combined WT plus Q196P-mutant EBF1 (purple). Expression levels of EBF1 
and TERT are shown.
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Figure 5. EBF1 binds to a TERT 5′ proximal cis-regulatory element. (A) De 
novo binding motif analysis of 2 GC cell lines revealed significant enrich-
ment of EBF1-binding motifs. An EBF1 consensus motif from the HOMER 
database is shown. P values were calculated using a hypergeometric test. 
(B) EBF1 ChIP-Seq data showed EBF1 binding to the TERT 5′ proximal 
region (highlighted by a yellow bar) in 4 GC cell lines (HGC27, Hs746T, YCC11, 
and AGS with endogenous EBF1) and also in AGS cells overexpressing WT 
EBF1 but not Q196P- or R209Q-mutant EBF1. DNA-binding motifs (dashed 
lines) of EBF1 were identified within these regions. (C) Gene expression 
(RNA-Seq) and H3K27ac and H3K4me1 enrichment signals at the TERT 
locus for primary tumor and matched normal samples and GC cell lines. 
The green and yellow highlights indicate EBF1-binding peaks 1 and 2 
in the TERT 5′ proximal region, respectively. Gray highlight indicates a 
previously described distal TERT regulatory element. (D) Line plots show 
detected cis interactions from the capture point (blue) at the TERT TSS 
to EBF1-binding peaks 1 and 2 (green and yellow bars, respectively) and 
the distal TERT-regulatory element. Interaction strength in units of reads 
per million (RPM) is represented in the y axis. (E) CapSTARR-Seq showed 
reporter activity at EBF1-binding peak 2. Black bar indicates the cloned 
TERT 5′ proximal region. Peaks within the yellow highlighted area indicate 
reporter activity in 2 GC cell lines. Q values were calculated using a Poisson 
distribution statistical test.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 1jci.org
and 1 GC cell line (LMSU) that had somatic deletions or rearrange-
ments affecting the TERT 5′ proximal region including peaks 1 and 
2 (Figure 6). In GC P990489, the deletion was a highly focal 1-kb 
deletion, occurring at –3.5 to –4.4 kb, coinciding with peak 2 (Fig-
ure 6A), whereas LMSU cells harbored a genomic rearrangement 
deleting both peak 1 and peak 2 (Figure 6B). For both GC P990489 
and LMSU cells, the 5′ TERT alterations  were orthogonally con-
firmed by Sanger sequencing (Figure 6, C and D). At the expres-
sion level, GC P990489, harboring a deletion of the TERT 5′ prox-
imal region, had the second-highest level of TERT overexpression 
in our in-house cohort (>8 fold higher compared with matched 
normal samples) (Figure 6E), and LMSU GC cells had high TERT 
mRNA expression, ranking 11th in our in-house panel of 63 gastric 
cell lines (Supplemental Figure 1B). We also performed telomere 
length measurements and observed an increase in GC P990489 
telomere lengths compared with those of matched normal tissue 
(Figure 6F). The third GC (HK-PFG144T) also harbored a dele-
tion affecting both peaks (Supplemental Figure 6A). These results 
suggest that in certain GCs, the TERT 5′ proximal region con-
taining peaks 1 and 2 is associated with genomic deletions and/
or rearrangements, which are predicted to delete and rearrange 
EBF1-binding sites.
To functionally test the role of peak 1 and peak 2 in TERT 
regulation, we performed CRISPR-mediated genomic dele-
tion of both peaks 1 and 2 in a GC cell line (YCC11) express-
ing low levels of TERT. Data from multiple single-cell clones, 
with homozygous deletion of both TERT regions, consis-
tently showed upregulated TERT expression compared with 
intact clones (P < 0.05; Figure 6G). We further introduced 
CRISPR-mediated point mutations to disrupt the EBF1-bind-
ing motifs of both regions in YCC11 cells (see Methods). After 
sequence verification (Supplemental Figure 6B), we analyzed 
single-cell clones with mutations in at least 1 allele in either or 
both of the peak 1 and peak 2 EBF1-binding motifs (i.e., peak 1, 
heterozygous; peak 2, heterozygous; peaks 1 and 2, heterozy-
gous; peak 2, homozygous). Using qPCR to access TERT expres-
sion, we detected higher TERT expression levels across all the 
mutated clones compared with levels in WT clones (P < 0.05; 
Figure 6H). These results suggest that both peaks probably con-
tribute to TERT regulation.
To determine whether the TERT 5′ proximal region is also 
associated with genomic alterations in other cancers, we surveyed 
published studies across 32 cancer types (19, 53) and identified 10 
more cases with genomic rearrangements affecting the TERT 5′ 
proximal region. These included 2 chromophobe renal cell carci-
nomas (KICH, TCGA), 1 urothelial bladder cancer (BLCA, TCGA), 
2 sarcomas (SARC, TCGA), 2 hepatocellular carcinomas (LIHC, 
TCGA), and 3 neuroblastomas (NBL) (Figure 6I), suggesting that 
the TERT 5′ proximal region is associated with genomic alter-
ations in other cancer types besides GC. Notably, in a total of 13 
cases, genomic alterations affected both peaks 1 and 2 in 11 cases 
and peak 2 in 2 cases, indicating the importance of both peaks in 
contributing to TERT regulation.
Discussion
TERT overexpression is a signature hallmark of cancer. In GC, 
Gigek et al. reported that TERT expression was detected in 80% 
tissue (Figure 5C, yellow bar) and also in cell lines with high TERT 
expression (KATO III and SNU16) compared with cell lines with 
low TERT expression (SNU719, YCC11, and YCC10). H3K27ac 
signals were also observed at peak 1 in the TERT-expressing lines 
KATO III and SNU16. To determine whether chromatin accessi-
bility at the TERT locus correlates with TERT transcription, we 
performed ATAC-Seq on 6 GC cell lines with high or low TERT 
expression. We observed higher levels of chromatin accessibility 
across the TERT locus (including the 5′ proximal region contain-
ing peaks 1 and 2) in cell lines with high TERT expression (Sup-
plemental Figure 5B, blue bar) and lower levels of chromatin 
accessibility in cell lines with low TERT expression. To assess 
whether DNA modifications, such as 5-methylcytosine (5mC) 
and 5-hydroxymethyl (5hmC), also correlate with TERT expres-
sion, we next performed 5mC and 5hmC profiling on cell lines 
with high or low TERT expression. However, we did not observe 
5mC or 5hmC signals in this proximal element with EBF1-binding 
peaks, in cell lines with either high or low TERT expression (Sup-
plemental Figure 5D and see Discussion). It is possible that TERT 
expression in GC is uncorrelated with DNA methylation levels or, 
alternatively, that because TERT is a low-expression gene  (49), 
changes in TERT DNA methylation were below the limits of detec-
tion of the 5mc and 5hmc profiling methods used in this study.
We asked whether the TERT TSS might interact with the peak 
1 and 2 regions via chromatin interactions (50). Applying Cap-
ture-C technology on 4 GC cell lines (AGS, SNU16, SNU484, and 
YCC11) targeting the TERT TSS, we confirmed that both peaks 1 
and 2 had chromatin interactions with the TERT TSS (Figure 5D 
and see Methods). However, despite occurring more distal to the 
TERT TSS, peak 2 showed stronger TSS interactions compared 
with peak 1. This suggests that although both peaks 1 and 2 may 
contribute to TERT regulation, peak 2 may play a stronger role, 
consistent with peak 2 having stronger epigenomic signals of 
enhancers (Figure 5C). To determine whether peak 2 had prop-
erties of a functional enhancer, we also applied CapSTARR-Seq 
technology, a high-throughput technique for functional testing of 
candidate enhancer elements (see Methods). Using this approach, 
peak 2 was confirmed to have enhancer activity (SNU16, Q = 1.58 
× 10–8; OCUM1, Q = 7.9 × 10–12; Figure 5E). Interestingly, although 
YCC11 is a cell line expressing low levels of TERT, we observed 
similar levels of cis interactions compared with cell lines express-
ing high levels of TERT (SNU16, SNU484, and AGS), supporting 
recent studies showing that many cis interactions are largely sta-
ble and preformed (51, 52). To explore global chromatin interac-
tion landscapes in the TERT locus, we also performed Hi-C chro-
matin conformation profiling in cell lines with high (SNU16) and 
low (SNU719) TERT expression. Hi-C interactions at the TERT 
locus were higher in SNU16 cells than in SNU719 cells (Supple-
mental Figure 5C).
Genomic alterations of the TERT 5′ proximal region in primacy 
GC. In other cancers, large-scale genomic alterations at the TERT 
locus (e.g., translocations, copy number variants) have been shown 
to deregulate TERT expression (19, 20). To investigate whether 
the TERT 5′ proximal region containing peaks 1 and 2 might be 
associated with genomic alterations in vivo, we examined struc-
tural variants (SVs) at the TERT locus in 212 primary GCs and 62 
cell lines (25). We identified 2 GCs (P990489 and HK-PFG144T) 
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(54). Besides B cell development (55), EBF1 has been reported 
to regulate adipocyte differentiation and morphology (56, 57) 
and also the differentiation of sensory neurons (58), highlight-
ing a role for EBF1 beyond the hematopoietic system. Supporting 
these findings, in vivo studies of EBF1 in Ebf1+/− mice on a high-fat 
diet revealed white adipose tissue (WAT) hypertrophy and insu-
lin resistance (57). In addition, late Ebf1−/− embryos were shown 
to have specific increases in striatal cell death and reductions in 
size after birth (58). In cancer, EBF1 has been proposed as a poten-
tial tumor suppressor (28) in malignancies such as breast cancer, 
in which EBF1 genomic deletions have been reported in 18.9% 
of breast cancer lines (29). EBF1 has also been proposed as an 
important epigenetic modifier in breast cancer (59), and in chol-
angiocarcinoma (CCA), EBF1 downregulation through prolonged 
oxidative stress was reported to induce tumorigenic properties 
(60). Interestingly, besides GC, analysis of RNA-Seq data across 
other TCGA cancer types revealed similar negative correlations 
between EBF1 and TERT (Supplemental Figure 6C). EBF1 may 
thus regulate TERT in other cancer types, although this hypothesis 
will require further investigation.
Our data suggest that in GC, EBF1 is downregulated in primary 
tumors particularly through epigenetic silencing. Specifically, at 
the level of DNA promoter hypermethylation, approximately half 
(40%–55%) of primary GCs with loss of EBF1 expression exhibited 
high levels of EBF1 promoter methylation.
Besides being silenced by epigenetic regulation, EBF1 was 
also found to exhibit somatic mutations resulting in dominant- 
negative isoforms. We observed EBF1 somatic point mutations in 
3.1% of GCs, half of which occurred within the highly conserved 
EBF1 DBD. Functional experiments support the notion that some of 
these mutations (e.g., Q196P) strongly abrogate the ability of EBF1 
to inhibit cell proliferation. Notably, although these EBF1 muta-
tions were heterozygous, we found that they had dominant-nega-
tive activity, which is likely explained by the fact that EBF1 protein 
acts as a dimer (43). In the literature, other examples of “single-hit” 
tumor suppressors include FBXW7 (61) and p53 (62), which also 
result in the creation of dominant-negative isoforms. We also note 
that the presence of functional somatic EBF1 mutations in GC 
provides further support for EBF1 activity in the stomach.
A third and distinct mechanism of abrogation of EBF1 function 
occurred through deletions and rearrangements of EBF1-binding 
sites proximal to the TERT promoter. Specifically, we identified a 
regulatory element close to the TERT promoter that interacts with 
the TERT TSS, containing EBF1-binding sites and demonstrating 
EBF1 occupancy. CRISPR-mediated deletion of this region, or 
CRISPR-induced mutations of EBF1-binding motifs in either or 
both peaks, resulted in increased TERT expression in GCs express-
ing low levels of TERT. Epigenomic analysis revealed that this 
region was silenced in GCs with low TERT expression and active 
in GCs with high TERT expression, raising the possibility that this 
TERT 5′ proximal region may function as a regulatory “rheostat,” 
recruiting transcriptional repressors or activators in GCs express-
ing low and high levels of TERT, respectively. Importantly, this 
region exhibited somatic deletions and rearrangements in cer-
tain GCs and other tumor types, confirming its disruption in vivo. 
Interestingly, for LMSU cells, analysis of in-house H3K27ac ChIP-
Seq data on GC cell lines suggested that, besides deleting this 
of gastric tumors but not in normal gastric mucosa (24), and other 
studies have also reported significant TERT overexpression in GC 
(22, 23). In this study, we performed a comprehensive analysis of 
TERT expression in GC. We queried RNA-Seq data from TCGA 
cohort and confirmed that TERT was significantly overexpressed 
in GC and that all 4 GC molecular subtypes exhibited significantly 
higher TERT expression levels than those in normal samples. 
We further replicated these findings in an independent RNA-Seq 
data set of 18 T/N pairs. Studies in different tumor types have 
highlighted distinct mechanisms for TERT transcriptional reac-
tivation. At the cis-regulatory level, TERT promoter mutations at 
C250T and C228T have been primarily observed in glioblastoma 
(89%), melanoma (72%), and bladder cancer (70%) (16, 17), creat-
ing de novo binding motifs for ETS TFs and activating TERT (41). 
In other tumor types such as neuroblastoma, lung cancer, colon 
cancer, and cervical cancer, studies have reported large-scale SVs 
and copy number alterations involving TERT that can also cause 
high expression of TERT by affecting noncoding regulatory ele-
ments at the TERT locus (19, 20). However, specific mechanisms 
underlying TERT reactivation in GC remain largely unknown. In 
this study, we identified the TF EBF1 as a direct repressor of TERT 
expression. Our results also suggest that in GC, TERT is reactivated 
by abolishing EBF1 function via at least 3 distinct mechanisms: 
(a) epigenetic silencing of EBF1 expression via PRC2, DNA meth-
yltransferase, and HDAC activity; (b) somatic EBF1 mutations 
resulting in dominant-negative isoforms; and (c) deletion or rear-
rangement of EBF1-binding sites proximal to the TERT promoter.
The discovery of EBF1 as a TERT repressor is notable. To date, 
4 EBF family TFs have been described (EBF1, EBF2, EBF3, and 
EBF4) and shown to play important developmental roles in the 
regulation of cell fate decisions, differentiation, and migration 
Figure 6. Genomic alterations of the TERT 5′ proximal region in primacy 
GC. (A) Somatic large-scale genomic deletion affecting EBF1-binding 
peak 2 in GC T990489. Tracks 1 and 3: aligned read coverage from WGS 
profiles. Tracks 2 and 4: distribution of aligned reads. Red reads in track 4 
have larger-than-expected inferred sizes and therefore indicate possible 
deletions. Lower coverage in track 3 with respect to track 1 at the same 
loci supports the existence of a somatic genomic deletion. Purple box 
indicates the genomic deleted region. (B) Translocation disrupting the 
TERT 5′ proximal region (including both EBF1-binding peaks 1 and 2) in 
LMSU cells. Blue bars indicate breakpoints of the translocation. Dark pink 
tracks depict H3K27ac signals. (C and D) Validation of somatic genomic 
deletion/translocation of the TERT 5′ proximal region in GC T990489 and 
LMSU lines via Sanger sequencing. (E) Log-transformed fold change of 
TERT expression in 18 GCs with respect to matched normal samples. GC 
P990489 is highlighted in yellow. (F) Telomere lengthening was observed 
in GC T990489 by Southern blotting and densitometric analysis. (G) 
The CRISPR-deleted region is indicated by scissors (top). Graph shows a 
comparison of TERT expression between WT YCC11 clones (black bars) and 
clones (C1, C2, C3) with CRISPR-mediated homozygous deletions at the 
TERT 5′ proximal region (brown bars). (H) Comparison of TERT expression 
between WT clones (black) and clones with mutations in at least 1 allele 
in 1 or both EBF1-binding motifs (blue). (I) Deletions/translocations that 
overlapped with the TERT 5′ proximal region are shown for 2 GC cases, 
1 GC cell line, and 10 cases of other cancer types. Vertical red and yellow 
lines highlight EBF1-binding peaks 1 and 2. *Q < 0.05, by 2-sided t test 
with FDR multiple testing correction (G and H). RT-PCR results are shown 
as the mean ± SD of technical triplicates. Figures are representative of 3 
independent experiments.
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2 groups. For cell phenotype assays, tumor xenograft studies, qPCR 
assays, real-time TRAP assays, and immunohistochemical analy-
ses, P values were calculated using a 2-sided t test. A P value of less 
than 0.05 was considered statistically significant. FDR-based mul-
tiple testing correction was applied for multiple comparisons when 
applicable. A Q value of less than 0.05 was considered statistically 
significant. For comparison of gene expression levels between tumor 
samples and normal samples in Figure 1A, a Wilcoxon’s rank-sum 
test with multiple testing correction using the FDR procedure was 
performed against normal expression levels. For comparison of gene 
expression levels between all tumor samples and normal samples in 
Figure 1H and Supplemental Figure 1A, a Wilcoxon’s rank-sum test 
was performed against normal expression levels. For the correlation 
analysis in Figure 1C and Supplemental Figure 6C, P values for cor-
relation were calculated using Pearson’s correlation test. For correla-
tion analysis in Figure 1B and Figure 2A, P values for correlation were 
calculated using Pearson’s correlation test with multiple testing cor-
rection with the FDR procedure.
Histone ChIP-Seq, TF ChIP-Seq, Capture-C, CapSTARR-Seq, 
and RNA-Seq data sets are available in the Gene Expression Omni-
bus (GEO) database (GEO GSE121140). The public data sets used are 
described in the Supplemental Methods.
Study approval. Patients’ primary samples were obtained from 
the SingHealth tissue repository with approval from the SingHealth 
Centralised IRB and signed patient informed consent. Animal stud-
ies were conducted in compliance with animal protocols approved by 
the SingHealth IACUC of Singapore. Additional details, including the 
methods associated with WGS and structural variant detection, ChIP-
Seq, RNA-Seq, telomere length measurements, Capture-C, CRISPR/
Cas9, silencing and overexpression of EBF1, tumor xenografts, DNA 
methylation analysis, real-time TRAP assays, drug treatments, Cap-
STARR-Seq, MD simulations, MethylLight assays, ATAC-Seq, EMSAs, 
detection of EBF1 coding mutations, EBF1 immunohistochemistry, 
Western blotting, Sanger sequencing, cell phenotype assays, qPCR, 
and data availability are described in the Supplemental Methods.
Author contributions
MX, WFO, JT, SL, BTT, and PT conceptualized the study. MX, 
WFO, JT, AQ, PHL, CX, NP, JQL, XY, MA, LMN, TS, CGAN, MR, 
LM, TN, TY, KD, JSL, KW, SGR, MB, RSYF, HIG, AJS, SL, and PT 
developed methodology. MX, WFO, AQ, PHL, JQL, YAG, KKH, 
SWTH, KJL, TN, MMC, JSL, and AJS analyzed data. MX, JT, ZL, 
JW, MR, LM, GF, GCW, SZ, TY, KD, ZFAI, JW, PPSY, YNL, STT, 
ML, ALKT, and XO performed experiments. MX and PT wrote the 
manuscript. PT supervised the study.
Acknowledgments
We thank Yoshiaki Ito and Shing Leng Chan for helpful discus-
sions. We thank Angie Tan, Beatrice Tan, and Hui Hoon Chua 
for their administrative support. We also thank members of the 
Duke-NUS Genome Biology Facility and the Sequencing and Sci-
entific Computing teams at the Genome Institute of Singapore for 
providing sequencing services and data management capabilities. 
This work was supported by National Medical Research Council 
grants TCR/009-NUHS/2013, OFLCG18May-0003, NMRC/
STaR/0026/2015, and OFIRG15nov072; National Universi-
ty Cancer Institute, Singapore (NCIS) grant NR13NMR111OM; 
TERT 5′ proximal region, genomic rearrangements in these cells 
may also cause genomic fusion of the 5′ TERT region with 2 distal 
superenhancers (Figure 6B). Genomic disruptions of this region 
may be required for high TERT expression, as the TERT upstream 
region is well known to show strong epigenetic repression across 
multiple cell types (63).
In conclusion, telomerase has attracted interest as a target for 
cancer therapy, as most somatic cells have no or only low-level 
telomerase activity, whereas up to 90% of human cancers have 
transcriptionally reactivated TERT. Numerous telomerase-based 
therapeutic strategies are under investigation, such as the telo-
merase inhibitor imetelstat (GRN163L) and telomerase-derived 
anticancer peptide vaccines (GV1001 and GRNVAC1) (64). How-
ever, recent clinical trial results for GRN163L have shown signif-
icant dose-dependent hematological side effects, liver function 
abnormalities, and other adverse effects (65), which may be due 
to simultaneous inhibition of telomerase activity in both cancer 
cells and normal tissue–specific stem/progenitor cells. Thus, there 
remains an urgent need to elucidate the basic mechanisms of telo-
merase reactivation in cancer, which may highlight new strategies 
to inhibit telomerase. In particular, combinatorial inhibition of 
epigenetic pathways regulating EBF1 expression may prove to be 
an interesting area for further study.
Methods
Cell lines. AGS, KATO III, SNU16, and Hs746T cells were obtained 
from the American Type Culture Collection (ATCC). SNU719 and 
SNU484 cells were obtained from the Korean Cell Line Bank (KCLB). 
LMSU, GSS, and HGC27 cells were obtained from the RIKEN cell 
bank. IM95 cells were obtained from the Japanese Collection of 
Research Bioresources (JCRB) Cell Bank. YCC10 and YCC11 cells 
were gifts from Yonsei Cancer Centre (Seoul, South Korea). Cell line 
identities were confirmed by short tandem repeat (STR) DNA profiling 
performed at the Centre for Translational Research and Diagnostics 
(Cancer Science Institute of Singapore, Singapore), and STR profiles 
were assessed according to the standard American National Standards 
Institute/ATCC (ANSI/ATCC) ASN-0002-2011 nomenclature. The 
profiles of cell lines showed greater than 80% similarity to reference 
databases. All cell lines were negative for mycoplasma contamination.
Statistics. For Capture-C data analysis, r3Cseq was used to iden-
tify significant interactions of the viewpoint against a scaled back-
ground (Q < 0.05). For CapSTARR-Seq data analysis, an enhancer 
peak was called when there was significant enrichment of fragments 
from 1 region in the output library compared with the representation 
of that region in the input library based on Poisson distribution using 
MACS2 (https://github.com/taoliu/MACS/). Histone ChIP-enriched 
peaks were detected using the control-based ChIP-Seq analysis tool 
CCAT (https://github.com/vanbug/cluster/tree/master/cluster/
CCAT/CCAT3.0) (FDR <5%). TF ChIP-enriched peaks were detected 
using MACS2 with the following thresholds: Q < 0.05 for paired-end 
sequencing and P < 0.00005 for single-end sequencing. TF-binding 
motifs were predicted using detected TF-binding sites from ChIP-Seq 
and HOMER (Hypergeometric Optimization of Motif EnRichment; 
http://homer.ucsd.edu/homer/motif/) with default parameters. 
For the immunohistochemistry studies in Supplemental Table 1, a 
Mann-Whitney U test was used for comparisons between 2 groups, 
whereas a Kruskal-Wallis test was used for comparisons of more than 
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